Key Points
- Insider selling: SVP Adam Veness sold 16,167 Dianthus Therapeutics shares for approximately $1.78 million, reducing his direct ownership by 80.84% to 3,833 shares.
- Analyst sentiment remains positive: HC Wainwright raised its price target to $158, while the company carries a “Moderate Buy” consensus rating and an average target of $124.27.
- Financial performance was weak: Dianthus reported a quarterly loss of $0.90 per share, missing estimates by $0.05, despite revenue of $0.76 million exceeding expectations.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) Director Simon Read sold 2,777 shares of the firm's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $109.55, for a total transaction of $304,220.35. Following the completion of the sale, the director owned 2,777 shares in the company, valued at approximately $304,220.35. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Dianthus Therapeutics Trading Down 3.0%
Shares of DNTH stock opened at $108.49 on Wednesday. Dianthus Therapeutics, Inc. has a 1 year low of $19.00 and a 1 year high of $114.55. The firm's fifty day simple moving average is $95.71 and its 200 day simple moving average is $81.79. The firm has a market capitalization of $5.93 billion, a P/E ratio of -26.14 and a beta of 1.22.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.
Institutional Investors Weigh In On Dianthus Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of DNTH. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock valued at $280,000 after buying an additional 618 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Dianthus Therapeutics by 13.2% during the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company's stock valued at $1,009,000 after acquiring an additional 6,323 shares in the last quarter. Invesco Ltd. boosted its position in shares of Dianthus Therapeutics by 31.1% during the 2nd quarter. Invesco Ltd. now owns 20,940 shares of the company's stock valued at $390,000 after acquiring an additional 4,962 shares in the last quarter. Alliancebernstein L.P. increased its stake in Dianthus Therapeutics by 14.5% in the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company's stock valued at $21,887,000 after acquiring an additional 149,200 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in Dianthus Therapeutics in the second quarter valued at about $27,000. Institutional investors own 47.53% of the company's stock.
Dianthus Therapeutics News Roundup
Here are the key news stories impacting Dianthus Therapeutics this week:
- Positive Sentiment: HC Wainwright issued an optimistic estimate for Dianthus Therapeutics’ earnings, offering a potential bullish catalyst for DNTH. However, the report did not provide specific revised earnings targets. HC Wainwright Issues Optimistic Estimate for DNTH Earnings
- Neutral Sentiment: Reported short interest was zero shares as of August 11, unchanged from the prior reporting period, with a days-to-cover ratio of zero. This indicates little evidence of active short-selling pressure or a potential short squeeze in DNTH.
- Negative Sentiment: Several insiders sold shares around $109 to $111. Senior Vice President Adam M. Veness sold 20,000 shares across transactions on August 7 and August 10 for approximately $2.21 million, reducing his position by roughly 80.8% overall. SEC insider trading filing
- Negative Sentiment: Director Simon Read sold 2,777 shares for about $304,000, cutting his holdings by 50%. Director Anne McGeorge sold 7,750 shares for approximately $845,000, reducing her position by about 86%. The timing and size of these sales could raise concerns because they occurred while the stock was trading near its 12-month high. SEC director trading filing
Wall Street Analyst Weigh In
A number of brokerages have recently commented on DNTH. Truist Financial upped their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Guggenheim reissued a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wolfe Research restated an "outperform" rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. TD Cowen reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Dianthus Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $124.27.
View Our Latest Report on Dianthus Therapeutics
About Dianthus Therapeutics
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
